AGEN

Agenus Inc. Common Stock

$6.50

Current Price

All

AI analysis

Read what the AI thinks of Agenus Inc. Common Stock in the app.

Analyses are generated by AI from public data and are not investment advice.

Get the app

Key figures

Dividend per share

—

Yield

—

EPS

$2.65

P/E

3.6

Data as of Oct 8

Why it matters for the long term

Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.

Upcoming events

Quarterly earnings

Expected EPS: -$0.25

Nov 9

Posts

No posts about AGEN yet.

About Agenus Inc. Common Stock

Agenus is a US biotechnology company that develops immune-system cancer treatments, including antibody drugs designed to help the body's own defenses attack tumors. It has no large steady product sales. Its revenue comes mostly from partnership deals, licensing payments, and milestone fees from drugmakers who pay for rights to its experimental medicines.